美国肺结节病住院与院内死亡趋势(2007-2018)
基于美国全国住院患者样本(2007-2018)分析肺结节病患者的住院与院内死亡趋势。肺结节病住院率由258.5/100万住院升至705.7/100万,呼吸衰竭住院增加九倍、机械通气增加三倍;全因院内死亡2.6%,呼吸衰竭者死亡高13倍、需机械通气者高26倍,但呼吸衰竭相关院内死亡下降50%。
要点
- 肺结节病住院及呼吸衰竭住院逐年增加,呼吸衰竭住院增加九倍
- 呼吸衰竭与机械通气显著抬高院内死亡风险
- 呼吸衰竭相关院内死亡从2007年17.2%降至2018年6.6%
核心结论
- 肺结节病患者呼吸衰竭住院增加,但呼吸衰竭相关院内死亡下降
- 高龄、呼吸衰竭、肺动脉高压和衰弱是院内死亡的重要预测因素
研究设计与样本
- 基于美国全国住院患者样本(National Inpatient Sample)2007-2018年住院数据的趋势分析
- 研究对象为肺结节病住院患者,院内死亡按年龄、呼吸衰竭、机械通气、医院位置与类型分层
- 采用Cochran-Armitage趋势检验评估死亡、呼吸衰竭与机械通气需求的线性趋势
主要发现
- 肺结节病住院由2007年258.5/100万住院升至2018年705.7/100万住院
- 呼吸衰竭住院由25.9/100万住院升至239.4/100万住院,增加九倍
- 机械通气需求由2007年9.4/100万住院升至2018年29.4/100万住院,增加三倍
- 全因院内死亡为2.6%;呼吸衰竭者10.6%对0.8%,为13倍;需机械通气者31.2%对1.2%,为26倍
- 呼吸衰竭相关院内死亡由2007年17.2%降至2018年6.6%,下降50%
关键数值与推荐
- 独立院内死亡预测因素:高龄(aHR 1.025)、呼吸衰竭(aHR 3.12)、需机械通气(aHR 6.01)、肺动脉高压(aHR 1.44)、肺栓塞(aHR 1.61)、衰弱(aHR 3.10)
临床怎么用
- 对肺结节病住院患者应关注呼吸衰竭与机械通气风险,并识别高龄、肺动脉高压、肺栓塞与衰弱等高死亡风险人群
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcoidosis-related hospitalizations have been increasing in the past decade. There is a paucity of data on mortality trends over time in patients with pulmonary sarcoidosis and respiratory failure who are hospitalized. RESEARCH QUESTION: What are the national temporal trends over time in hospitalization and inpatient mortality rates in patients with pulmonary sarcoidosis and respiratory failure hospitalized in the United States between 2007 and 2018? STUDY DESIGN AND METHODS: Hospitalization data between 2007 and 2018 were extracted from the National Inpatient Sample for subjects with pulmonary sarcoidosis. Inpatient mortality was stratified by age, respiratory failure, mechanical ventilation (MV), hospital location, and setting (rural vs urban, academic vs nonacademic). A Cochran-Armitage test for trend was used to assess the linear trend in mortality, respiratory failure, and need for MV. RESULTS: Hospitalizations in patients with pulmonary sarcoidosis increased from 258.5 per 1,000,000 hospitalizations in 2007 to 705.7 per 1,000,000 in 2018. Hospitalizations for respiratory failure increased ninefold from 25.9 to 239.4 per 1,000,000 hospitalizations, and the need for MV increased threefold from 9.4 per 1,000,000 in 2007 to 29.4 per 1,000,000 in 2018. All-cause inpatient mortality was 2.6%; however, mortality was 13 times higher in patients with respiratory failure (10.6% vs 0.8%) and 26 times higher in patients who required MV (31.2% vs 1.2%). Inpatient mortality associated with respiratory failure declined 50% from 17.2% in 2007 to 6.6% in 2018. Independent inpatient mortality predictors were older age (adjusted hazard ratio [aHR], 1.025), respiratory failure (aHR, 3.12), need for MV (aHR, 6.01), pulmonary hypertension (pHTN; aHR, 1.44), pulmonary embolism (aHR, 1.61), and frailty (aHR, 3.10). INTERPRETATION: Hospitalizations for respiratory failure in patients with pulmonary sarcoidosis are increasing; however, inpatient mortality from respiratory failure has declined. Older age, respiratory failure, pHTN, and frailty are important predictors of inpatient mortality in patients with pulmonary sarcoidosis who are hospitalized.
引用
- Alqalyoobi S, Liao SY, Qureshi W, et al. National Temporal Trends in Hospitalization and Inpatient Mortality in Patients With Pulmonary Sarcoidosis in the United States Between 2007 and 2018. Chest. 2021. PMID: 34364869. doi:10.1016/j.chest.2021.07.2166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。